| P2093 | author name string | R. N. Jones | |
| | E. J. Baron | |
| P2860 | cites work | Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam | Q35360429 |
| | Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections | Q36758337 |
| | Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential | Q40389389 |
| | Enterococcal infections. The increasing threat of nosocomial spread and drug resistance | Q40882752 |
| | Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations. | Q54232073 |
| | Increasing problems in the therapy of enterococcal infections. | Q54238980 |
| | Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases. | Q54331490 |
| | Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830). | Q54342222 |
| | Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group. | Q54629748 |
| | Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains | Q69364580 |
| | Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives | Q70188146 |
| | Susceptibility of beta-lactamase-producing enterococci to piperacillin with tazobactam | Q72251718 |
| | Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Sur | Q72369431 |
| | Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study | Q72544894 |
| | Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles | Q72570621 |
| | Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection | Q72574046 |
| | Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections | Q72951194 |
| | Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections | Q72956661 |
| | The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia | Q72956667 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 141-151 | |
| P577 | publication date | 1995-03-01 | |
| P1433 | published in | Diagnostic Microbiology and Infectious Disease | Q15763479 |
| P1476 | title | National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers | |
| P478 | volume | 21 | |